MID-VOLUME · SEX-BALANCED
crisaborole Side Effects
crisaborole (also sold as Eucrisa) sits MID-VOLUME #327 of 524 by FAERS report count. Lead signal: SEX-BALANCED - 65% of sex-coded reports are female (5,420 F / 2,864 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 9,400
- FAERS reports
FDA Adverse Event Reporting System extract for crisaborole. Stamp set WATCHLIST · DEATH-RARE · HOSP-LIGHT. How figures are compiled.
crisaborole reporting skew - 65% of sex-coded reports are female (5,420 F / 2,864 M). Volume band MID-VOLUME #327 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for crisaborole (Eucrisa) (9,400 reports). Signature SEX-BALANCED. Dominant age band on file: 0-17. Educational reference only.
Counts from the openFDA FAERS extract (2013–2025). Stamps WATCHLIST · DEATH-RARE · HOSP-LIGHT · SEX-BALANCED.
APPLICATION SITE PAIN leads 1,415 of 9,400 reports
Who reports · age peak 0-17 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 0-17 (2,166 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death is rare in this extract (24 / 9,400). Co-reported reactions in that thin subset:
| Reaction | Reports |
|---|---|
| DEATH | 19 |
| ACCIDENTAL DEATH | 2 |
| BURNING SENSATION | 2 |
| CONDITION AGGRAVATED | 2 |
| PRURITUS | 2 |
| ACNE | 1 |
| APPLICATION SITE PAIN | 1 |
| APPLICATION SITE PRURITUS | 1 |
| ASTHMA | 1 |
| COMA | 1 |
| DEAFNESS UNILATERAL | 1 |
| DEMENTIA | 1 |
| DRUG EFFECTIVE FOR UNAPPROVED INDICATION | 1 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 1 |
| DYSPNOEA | 1 |
| ERYTHEMA | 1 |
| INFLAMMATION | 1 |
| NEOPLASM MALIGNANT | 1 |
Reactions in Hospitalization Reports
Hospitalization is lighter here (142). Reactions in that subset:
| Reaction | Reports |
|---|---|
| ECZEMA | 22 |
| PRURITUS | 20 |
| RASH | 20 |
| FATIGUE | 18 |
| ERYTHEMA | 16 |
| CONDITION AGGRAVATED | 15 |
| ARTHRALGIA | 14 |
| DRUG HYPERSENSITIVITY | 14 |
| NASOPHARYNGITIS | 14 |
| PYREXIA | 14 |
| CHEST PAIN | 13 |
| PAIN | 13 |
| UPPER RESPIRATORY TRACT INFECTION | 13 |
| CELLULITIS | 12 |
| NAUSEA | 12 |
| PAIN IN EXTREMITY | 12 |
| URINARY TRACT INFECTION | 12 |
| HYPERSENSITIVITY | 11 |
How to read crisaborole FAERS figures (WATCHLIST · DEATH-RARE · HOSP-LIGHT)
FAERS holds 9,400 voluntary reports linked to crisaborole (Eucrisa), 2013-2025. Death is listed on 24 (0.3%). Hospitalization appears on 142 (1.5%). Top co-reported indication: Dermatitis Atopic.
Mid-volume extract - treat DEATH-RARE · HOSP-LIGHT as signal-detection rates next to 65% of sex-coded reports are female (5,420 F / 2,864 M).
Read with crisaborole
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-RARE · HOSP-LIGHT stamps.
ABS(total_reports) peer at 9,450 FAERS cases (Δ 50 heavier vs crisaborole); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-RARE · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 9,536 FAERS cases (Δ 136 heavier vs crisaborole); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-RARE · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 9,259 FAERS cases (Δ 141 lighter vs crisaborole); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-RARE · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 9,140 FAERS cases (Δ 260 lighter vs crisaborole); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-RARE · HOSP-LIGHT · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 61.9 pp vs crisaborole's DEATH-RARE): CASELOAD · HOSP-MID.
crisaborole stamps WATCHLIST · SEX-BALANCED; class peers and methodology beat restating the same FAERS caveats on every effects URL.